CClinicalTrials.gg
RecruitingNCT02012699iCaRe2Updated Jun 29, 2026

Integrated Cancer Repository for Cancer Research

An observational study in Pancreatic Cancer, Thyroid Cancer and Lung Cancer, sponsored by University of Nebraska. Recruiting at 42 sites in United States. Open to participants aged 19 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by University of Nebraska · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
999,999
Ages
19 Years to 110 Years
Sex
All
01

Study summary

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Read the detailed description

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2.unmc.edu) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred \& Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically interoperable and easily customizable cancer data resource, which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals.

The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries: Pancreatic Cancer Collaborative Registry (PCCR), Breast Cancer Collaborative Registry (BCCR), Thyroid Cancer Collaborative Registry (TCCR), and Great Plains Health Informatics Database (GPHID; to enroll subjects with no history of cancer diagnosis at time of enrollment). The repository now includes: Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal \& Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), Non-Melanoma Skin Cancer Registry (NMSC) and Auxiliary Cancer Registry (ACR).

The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data. The iCaRe2 provides a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; utilization of standard vocabulary and data elements; and ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.

02

Conditions studied

  • Pancreatic Cancer
  • Thyroid Cancer
  • Lung Cancer
  • Esophageal Cancer
  • Thymus Cancer
  • Colon Cancer
  • Rectal Cancer
  • Gastrointestinal Stromal Tumors
  • Anal Cancer
  • Bile Duct Cancer
  • Duodenal Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Liver Cancer
  • Small Intestine Cancer
  • Peritoneal Surface Malignancies
  • Familial Adenomatous Polyposis
  • Lynch Syndrome
  • Bladder Cancer
  • Kidney Cancer
  • Penile Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Ureter Cancer
  • Urethral Cancer
  • Hypopharyngeal Cancer
  • Laryngeal Cancer
  • Lip Cancer
  • Oral Cavity Cancer
  • Nasopharyngeal Cancer
  • Oropharyngeal Cancer
  • Paranasal Sinus Cancer
  • Nasal Cavity Cancer
  • Salivary Gland Cancer
  • Skin Cancer
  • Central Nervous System Tumor
  • Central Nervous System Cancer
  • Mesothelioma
  • Breast Cancer
  • Leukemia
  • Melanoma
  • Sarcoma
  • Unknown Primary Tumor
  • Multiple Myeloma
  • Ovarian Cancer
  • Endometrial Cancer
  • Vaginal Cancer
  • Neuroendocrine Tumors
  • Plasma Cell Dyscrasia
  • Healthy Control

Keywords

  • Pancreatic Cancer
  • Thyroid Cancer
  • Esophageal cancer
  • Thymus cancer
  • Pancreatic tumor
  • Esophageal tumor
  • Thymus tumor
  • Thyroid Tumor
  • Thyroid Nodule
  • Lung Tumor
  • Breast Cancer
  • Neuroendocrine tumor
  • Plasma Cell Dyscrasia
  • Healthy Control
03

Who can participate

Ages eligible
19 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Any individual who meets the eligibility criteria will be invited to participate in iCaRe2.

Inclusion criteria

  • Diagnosis/history of cancer
  • Risk for developing cancer or suspicious clinical findings
  • No history of cancer (normal control registry)
  • Able to provide informed consent
  • 19 years of age or older
  • English or Spanish speaking individuals

Exclusion criteria

Exclusion Criteria

  • Unable to provide informed consent because of cognitive impairment
  • Non-English or non-Spanish speaking individuals
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
999,999 participants (estimated)
Target follow-up
80 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. Development and Implementation of a Web-based Cancer Collaborative Registry

    This is a registry that will continue to accrue participants indefinitely.

    Time frame: 86 years

Secondary outcomes

  1. Procurement and Banking of Excess Biological Material for Future Analysis

    This is a registry that will continue to accrue participants indefinitely.

    Time frame: 86 years

Other outcomes

  1. Collection and Banking of Blood, DNA, and Urine Samples for Future Studies

    This is a registry that will continue to accrue participants indefinitely.

    Time frame: 86 years

06

Study locations

42 of 42 sites recruiting
  • Advent Health
    Greenwood Village, Colorado 80111, United States
    Recruiting
  • Hartford HealthCare Cancer Institute at Manchester Medical Hospital
    Manchester, Connecticut 06040, United States
    Recruiting
  • Florida Hospital Memorial Medical Center
    Daytona Beach, Florida 32117, United States
    Recruiting
  • Florida Hospital DeLand
    DeLand, Florida 32720, United States
    • Sandra Allten, RN,OCN,CCRP · Contact · sandra.allten@fhmmc.org · 386-231-3267
    • Erik Harris, MD · Principal investigator
    Recruiting
  • Florida Hospital FISH
    Orange City, Florida 32763, United States
    Recruiting
  • Florida Hospital Flagler
    Palm Coast, Florida 32164, United States
    Recruiting
  • Tallahassee Memorial Hospital
    Tallahassee, Florida 32308, United States
    Recruiting
  • Rush-Copley Cancer Care Center
    Aurora, Illinois 60504, United States
    Recruiting
  • Rush-Copley Healthcare Center
    Yorkville, Illinois 60560, United States
    Recruiting
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
    • Ellie Ross · Contact · ellie.ross@parkview.com
    • Brian Johnson, MD · Principal investigator
    • Melanie Clark, MD · Principal investigator
    Recruiting
  • Methodist Jennie Edmundson Hospital
    Council Bluffs, Iowa 51503, United States
    Recruiting
  • Covenant Medical Center, Inc
    Waterloo, Iowa 50702, United States
    Recruiting
  • Saint Luke's Cancer Instititute - South
    Overland Park, Kansas 66213, United States
    Recruiting
  • Northwest Hospital
    Randallstown, Maryland 21133, United States
    Recruiting
  • William E. Kahlert Regional Cancer Center
    Westminster, Maryland 21157, United States
    Recruiting
  • Holyoke Medical Center
    Holyoke, Massachusetts 01040, United States
    Recruiting
  • Riverwood Healthcare Center
    Aitkin, Minnesota 56431, United States
    Recruiting
  • Essentia Health-St. Joseph's Medical Center
    Brainerd, Minnesota 56401, United States
    Recruiting
  • Essentia Health - Duluth Clinic
    Duluth, Minnesota 55805, United States
    Recruiting
  • St. Luke's Hospital of Duluth
    Duluth, Minnesota 55805, United States
    Recruiting
  • Lake Region Healthcare
    Fergus Falls, Minnesota 56537, United States
    Recruiting
  • Saint Luke's Cancer Institute, East
    Kansas City, Missouri 64086, United States
    Recruiting
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
    Recruiting
  • Saint Luke's Cancer Institute, Kansas City North
    Kansas City, Missouri 64118, United States
    Recruiting
  • Saint Luke's Cancer Institute, Liberty
    Liberty, Missouri 64068, United States
    Recruiting
  • North Kansas City Hospital
    North Kansas City, Missouri 64116, United States
    Recruiting
  • Heartland Regional Medical Center dba Mosaic Life Care
    Saint Joseph, Missouri 64507, United States
    • Molly Kidwell · Contact · molly.kidwell@mymlc.com · 816-271-7654
    • Juliet Gyamfua Appiah, MD · Principal investigator
    Recruiting
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
    Recruiting
  • Mary Lanning Healthcare, Morrison Cancer Center
    Hastings, Nebraska 68901, United States
    Recruiting
  • Faith Regional Health Services, Carson Cancer Center
    Norfolk, Nebraska 68701, United States
    • Cynthia Montgomery, RN · Contact · cmontgome@frhs.org · 402-644-7534
    • Rahib C Fahed, MD · Sub investigator
    • Irena Popa, MD · Sub investigator
    Recruiting
  • Great Plains Regional Medical Center
    North Platte, Nebraska 69101, United States
    • Rebecca Dotson · Contact · dotsonr@gphealth.org · 308-696-7386
    • Kartik Anand, MD · Principal investigator
    Recruiting
  • Methodist Estabrook Cancer Center
    Omaha, Nebraska 68114, United States
    Recruiting
  • Nebraska Methodist Health System
    Omaha, Nebraska 68114, United States
    Recruiting
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    • Kurt Fisher, MD, PhD · Contact · kfisher@unmc.edu · 402-559-9025
    • Kurt Fisher, MD, PhD · Principal investigator
    Recruiting
  • C.R. Wood Cancer Center, Glens Falls Hospital
    Glens Falls, New York 12801, United States
    • Misty LaCross DeCaro, RN-BSN · Contact · mjlacross@glensfallshosp.org · 518-926-6529
    • Aqeel Gillani, MD · Contact · 518-926-6701
    • Aqeel Gillani, MD · Sub investigator
    Recruiting
  • Faxton St. Luke's Healthcare, Mohawk Valley
    Utica, New York 13501, United States
    Recruiting
  • Cape Fear Valley Health System
    Fayetteville, North Carolina 28304, United States
    Recruiting
  • Essentia Health
    Fargo, North Dakota 58103, United States
    Recruiting
  • Trinity Hospital Cancer Care Center
    Minot, North Dakota 58701, United States
    Recruiting
  • Aultman Alliance Community Hospital
    Alliance, Ohio 44601, United States
    Recruiting
  • Aultman Hospital
    Canton, Ohio 44710, United States
    Recruiting
  • Bellin Memorial Hospital
    Green Bay, Wisconsin 54305, United States
    Recruiting
07

References and documents

Related links

Individual participant data

Plan to share: Yes — All data and/or specimen request have to be made to the Principal Investigator of the center and follow the Human Subject Protection guidelines and policy.

Supporting information: Study protocol, Icf

08

Registry details

Key details

Study ID
NCT02012699
Lead sponsor
University of Nebraska
Responsible party
Sponsor
First posted
Dec 16, 2013
Start date
Nov 1, 2013
Primary completion
Dec 2099 (estimated)
Completion
Dec 2099 (estimated)
Last update
Jun 29, 2026

Study contacts

Artem Pachikov
Contact
artem.pachikov@unmc.edu
402-559-0568
Kurt Fisher, MD, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion